Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual Event

Jun 14, 2020 9:00 AM - Jun 18, 2020 5:00 PM

(Eastern Standard Time)

Fort Washington, PA 19034

DIA 2020 Global Annual Meeting

ON DEMAND - Best Practices for Randomization and Re-Randomization in Clinical Trials

Session Chair(s)

Yeh-Fong  Chen, PhD

Yeh-Fong Chen, PhD

Mathematical Statistician (Team Lead), Office of Translational Sciences, CDER

United States

Randomized clinical trials (RCT) are traditionally conducted in the context of demonstrating the efficacy and safety of medical products. Although RCT can effectively avoid confounding and are the gold standard, trial designers and analysts are not always trained on how to plan and implement randomization properly. In light of the increasing popularity of adaptive and enrichment designs with multiple stages, where updating the randomization ratio or re-randomizing the same or new patients is possible, it is important to monitor its practice and impact on ongoing trials. While Bayesian approaches (e.g., response-dependent randomization) in such designs have been increasingly considered, their perceived advantage or disadvantage over traditional frequentist approaches warrants more research. In this session, speakers from the industry, academia, and regulatory agencies are invited to discuss their research and viewpoints and share practical experiences.

Learning Objective : Recognize and achieve proper implementation of randomization, with the update of randomization ratio during a trial with multiple stages.

Speaker(s)

Linda L. Danielson, MS

Best Practices for Randomization: Pros and Cons of Minimization

Linda L. Danielson, MS

IDDI Inc, United States

Chief Operating Officer and Executive Vice President

Roy  Tamura, PhD

Clinical Trials with Multiple Randomization Schedules: Rationale and Implementation

Roy Tamura, PhD

University of South Florida, United States

Associate Professor of Biostatistics

H. M. James  Hung, PhD

FDA Update

H. M. James Hung, PhD

FDA, United States

Director, Division of Biometrics I, Office of Biostatistics, OTS, CDER

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.